A Non-comparative Phase II Trial Evaluating the Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age With an HIV-RNA Plasma Viremia Below 50 Copies/mL Under a Current Boosted Protease Inhibitor Containing Regimen (ANRS 163 ETRAL)

Trial Profile

A Non-comparative Phase II Trial Evaluating the Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age With an HIV-RNA Plasma Viremia Below 50 Copies/mL Under a Current Boosted Protease Inhibitor Containing Regimen (ANRS 163 ETRAL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Etravirine (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science.
    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top